(Albany, US) DelveInsight has launched a new report on “Alopecia Market Insights, Epidemiology and Market Forecast-2030”.

 

DelveInsight’s “Alopecia Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Alopecia, historical and forecasted epidemiology as well as the Alopecia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the facts:

• Androgenetic alopecia in men aged 40–69 years: prevalence and risk factors,” the prevalence of vertex and full androgenic alopecia increased with age from approximately 30% (age 40–55 years) to 50% (age 65–69 years).
• According to DelveInsight, alopecia areata affects as many as 6.8 million people in the US with a lifetime risk of 2.1%. People of all ages, both sexes and all ethnic groups can develop alopecia are ata.
• As DelveInsight, the prevalence of cicatricial alopecia in the US is 7%.

 

Request for free sample report: https://www.delveinsight.com/sample-request/alopecia-market

 

Scope of the Report

• The Alopecia report covers the descriptive overview of Alopecia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Alopecia epidemiology and Alopecia treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Alopecia are provided, along with the assessment of new therapies, which will have an impact on the current Alopecia treatment landscape
• A detailed review of Alopecia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Alopecia market

 

Hair loss also known as alopecia or baldness, refers to a loss of hair from part of the head or body. Typically, at least the head is involved, and the severity of hair loss can vary from a small area to the entire body.

About one-third of women experience hair loss at some time in their lives; among postmenopausal women, as many as two-thirds suffer hair thinning or bald spots. Hair loss in women often has a greater impact than hair loss does on men, because it is less socially acceptable for them. Alopecia can severely affect a woman’s emotional well-being and quality of life.

The condition occurs when white blood cells attack the cells in hair follicles, causing them to shrink and dramatically slow down hair production. It is unknown precisely what causes the body’s immune system to target hair follicles in this way.

There are different types of alopecia varying in terms of causes, severity (how much hair falls out), patterns of hair loss, the usual age it starts and body parts affected. Most of the people have alopecia areata, which is often used as an umbrella name for a spectrum (a range) of types: areata, totalis, and universalis. Because alopecia areata is a spectrum, many people had hair loss ‘in-between’ these named points. Some people found that their alopecia changed along the spectrum over time.

The extreme forms of alopecia areata are alopecia total is, which involves the loss of all head hair, and alopecia universal is, which involves the loss of all hair from the head and the body.

The main type of hair loss in women is the same as it is men.

 

Request for free sample report: https://www.delveinsight.com/sample-request/alopecia-market

 

Some of key companies are-

• Merck Pharma Co.
• Johnson & Johnson Co. 
• Samumed
• And Many Others

Name of drugs covered which are given below-

• Propecia (finasteride)
• Rogaine (Minoxidil)
• SM04554
• And Many Others

 

Request for free sample report: https://www.delveinsight.com/sample-request/alopecia-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Alopecia

3. Competitive Intelligence Analysis for Alopecia

4. Alopecia: Market Overview at a Glance

4.1. Alopecia Total Market Share (%) Distribution in 2017

4.2. Alopecia Total Market Share (%) Distribution in 2030

5. Alopecia: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Alopecia Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Alopecia Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Alopecia Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Alopecia Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Alopecia Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Alopecia Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Alopecia Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Alopecia Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Alopecia Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Alopecia Treatment and Management

8.2. Alopecia Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Alopecia Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Alopecia: Seven Major Market Analysis

13.1. Key Findings

13.2. Alopecia Market Size in 7MM

13.3. Alopecia Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Alopecia Total Market Size in the United States

15.1.2. Alopecia Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Alopecia Total Market Size in Germany

15.3.2. Alopecia Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Alopecia Total Market Size in France

15.4.2. Alopecia Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Alopecia Total Market Size in Italy

15.5.2. Alopecia Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Alopecia Total Market Size in Spain

15.6.2. Alopecia Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Alopecia Total Market Size in the United Kingdom

15.7.2. Alopecia Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Alopecia Total Market Size in Japan

15.8.3. Alopecia Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Alopecia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/alopecia-market